Insights from ai-PULSE 2025: Building for Real-world Deployment

Insights from ai-PULSE 2025: Building for Real-world Deployment Build • Maxime Eyraud • 02/03/26 • 5 min read

AI’s next phase is defined by deployment, not demos.

At ai-PULSE 2025 , leaders from defense, pharmaceuticals, music streaming, and automotive showed what happens when AI moves from labs into real-world environments. Whether flying a fighter jet or reshaping global content personalization systems, the constraint shifts from model capability alone to robustness and auditability. AI delivers impact only when embedded neatly inside existing operational systems, aligned with both internal policies and external regulation, and engineered for reliability under pressure.

This article brings together the key sessions that illustrated how AI is being applied across industries.

The First AI Flying a Production Fighter Jet

Thomas Palomares, AI Research Engineer at Helsing, presented the first AI system to fly a production fighter jet , a key milestone for real-world agentic AI. He reframed modern air combat as no longer a visual “dogfight", but a beyond-visual-range (BVR) environment shaped by partial observability, massive sensor data, and seconds-long decision cycles. As he put it, it is “less of a physical brawl, but more like a high-speed 3D chess game played in a hurricane.”

Helsing’s Centaur system is designed for this reality. Trained using reinforcement learning, the agent reasons under uncertainty and long-term dependencies while running entirely onboard the aircraft. It ingests the same inputs as a human pilot — mission objectives, sensor feeds, situational context — and outputs guidance, maneuver recommendations, and weapon-timing suggestions, with final validation remaining with the pilot.

The hardest challenge was bridging simulation and live flight . High-fidelity simulators alone proved insufficient, leading Helsing to build AI-first simulators optimized for scale and speed, compressing decades of engagements into days of training. Robustness was prioritized through extensive randomization, rather than perfect realism. Combined with a strict separation between certified flight-control systems and high-level tactical reasoning, this enabled successful live tests. The result, Palomares stressed, is “much more than just a better autopilot,” but a system designed to give human pilots a decisive informational edge . (▶️ Watch session in full )

Helsing's Thomas Palomares presented the first AI system to fly a production fighter jet.

From Molecules to Models: How AI Is Redesigning Pharmaceutical R&D

Joel Belafa, CEO, Biolevate

Antoine De Torcy, Chief AI Officer, Biolevate

Cédric Mahé, Senior Global Medical Expert, RWE and Partnerships, Sanofi Vaccines

Sophia Metz, Founder, Biostream

Moderated by Biostream founder Sophia Metz, this session explored how AI is reshaping pharmaceutical R&D, from epidemiological surveillance to drug discovery and vaccine design . Metz guided the discussion across public health, drug discovery, and regulated deployment, consistently grounding technical ambition in real-world constraints.

Cédric Mahé (Sanofi Vaccines) highlighted structural limits in public health surveillance: delayed data, siloed indicators, and underused digital signals. As he stressed, “the method to determine what is the best antigen to put in the vaccine has not changed a lot for the last 50 years…” Drawing on pilots using GP software, social media, wastewater testing, and private labs, he argued for real-time, multi-source epidemiology and AI-driven antigen selection.

Antoine de Torcy (Biolevate) explained why this requires more than deploying frontier LLMs. LLMs remain limited by context size and long reasoning chains, making complex biomedical problems unsolvable in one go. Biolevate’s approach combines structured knowledge navigation, next-generation vector stores, and agent orchestration to deliver traceable, reproducible workflows compatible with healthcare regulation.

Joel Belafa (Biolevate) anchored the discussion in impact: AI pipelines already run in production for compliance, literature review, and therapeutic discovery, including oncology programs reaching early preclinical validation. “We already filed patents based on discoveries we made with AI,” he shared.

Our speakers shared the same conviction: AI’s real leverage in pharma now lies in scalable, auditable systems that can operate reliably across science, industry, and public health. (▶️ Watch session in full )

ai-PULSE speakers discussed how AI is redisigning the pharmaceutical industry.

AI Everywhere: Reinventing Spotify's Core Strategies

For Spotify, AI is not about adding a single feature — it is reshaping the company’s core strategic pillars. As Romain Takeo Bouyer, Spotify's Global Head of Content Analytics, explained, AI now runs horizontally across personalization, ubiquity, and freemium, driving a major architectural shift “from prediction to reasoning.”

This transformation requires exposing real-time data at scale, redesigning interfaces for richer user input, and building more agentic systems. The result is a move from static recommendations to fluid interactions, embodied in the conversational DJ that lets listeners “ask about your listening history for the past 15 years” and get instant, contextual responses.

AI also accelerates Spotify’s ubiquity strategy, anchoring the service wherever users are. Features such as “Hey Spotify” and the service’s integration into ChatGPT extend listening and playlist creation into AI-native environments. On the monetization side, AI enhances the freemium funnel by powering premium-only features — such as Audiobooks Recap — that strengthen retention and make subscription economics more aligned with compute-intensive experiences. As Bouyer noted, Spotify’s long-standing marginal-cost model creates a natural synergy with subscription-based AI.

Finally, AI introduces new responsibilities. With 75 million tracks removed for abuse in 2025, Spotify is scaling enforcement systems, supporting DDEX metadata updates for AI transparency, and strengthening impersonation safeguards. Bouyer emphasized that innovation must go hand in hand with trust : the goal is not to replace artists but “to enhance the very human link between an artist and a listener.” (▶️ Watch session in full )

Spotify's Romain Takeo Bouyer discussed how AI is reshaping the company's core strategic pillars.

Open & Repurposable: Foundation Models for the…